NCT01627795暂停1 期
A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study
Oshadi Drug Administration1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Adverse events and serious adverse events occurence
研究概览
简要总结
Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of 4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless of the therapeutic approach.
The anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12 months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no dose-limiting toxicities observed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of malignant mesothelioma
- •Man or woman 21 years and above
- •Adequate performance status (ECOG 0, 1, or 2)
- •Patient must have adequate organ function as the following:
- •Absolute neutrophils counts (ANS) > 2500/μL.
- •Platelets > 150,000/μL.
- •Hemoglobin > 10 g/dL.
- •Total Bilirubin < 1.5 Upper Normal Limit (UNL).
- •Alanine aminotransferase (ALT), AST (aspartate aminotransferase)and alkaline phosphatase must be < 1.5 times of the upper limit of normal.
- •LDH (lactate dehydrogenase) < 500 int. unit/L
- •Estimated GFR (glomerular filtration rate) > 45 ml/min.
- •Written informed consent
- •Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
- •Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.
排除标准
- •Evidence of liver metastasis
- •Any bone involvement
- •Prior radiotherapy, cytotoxic or biologic systemic treatment
- •Any history of Asthma or COPD (chronic obstructive pulmonary disease) that needs systemic therapy with steroids for more than 2 weeks during the last 2 years.
- •Treatment with systemic steroids for more then 1 month during the last year.
- •Active smokers that are unable to quite smoking
- •Any treatment with investigational agent within 30 days prior to registration for protocol therapy.
- •Cerebrovascular accident, transient ischemic attack or myocardial infarction within 6 months prior to registration for protocol therapy.
- •Evidence of pulmonary embolism within 6 months prior to registration for protocol therapy.
- •Any history of solid or hematologic malignancies.
- •Patient with positive HIV serology at screening.
- •Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
- •Uncontrolled hypertension (> 150/100 mm Hg despite optimal medical therapy).
- •Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 grade
- •Patients in whom radiation or surgery is indicated
- •Significant swallowing disorders.
- •Small bowel surgery.
- •Suspicion of absorption disruption as a result of abdominal radiation
- •Pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
- •Evidence of concurrent (< 5 years) second malignancy
- •Mental disorders.
- •Inability to give written informed consent.
研究组 & 干预措施
Oshadi D and Oshadi R
Experimental
anti cancer agents
干预措施: Oshadi D and Oshadi R (Drug)
结局指标
主要结局
Adverse events and serious adverse events occurence
时间窗: One month following treatment initiation
Adverse events and serious adverse events report
次要结局
- overall survival time(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaAdvanced Malignant Pleural or Peritoneal MesotheliomaNCT04462809Hospices Civils de Lyon40
已完成
2 期
Diadem to Investigate the Activity and Safety of DurvalumabPleura MesotheliomaNCT04115111Mario Negri Institute for Pharmacological Research57
已完成
2 期
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaMesotheliomaPeritoneal MesotheliomaNCT05041062University of Chicago2
撤回
1 期
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural MesotheliomaMalignant Pleural MesotheliomaNCT01353482University College, London
Unknown
不适用
Mesothelioma and Radical Surgery 2MesotheliomaNCT02040272Royal Brompton & Harefield NHS Foundation Trust328